NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast announced a quarterly dividend on Thursday, September 6th. Shareholders of record on Friday, September 21st will be given a dividend of $0.48 per share on Thursday, November 8th. This represents a $1.92 annualized dividend and a yield of 1.21%. The ex-dividend date is Thursday, September 20th. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) issued its earnings results on Tuesday, November, 6th. The specialty retailer reported $1.14 earnings per share for the quarter, hitting analysts' consensus estimates of $1.14. The specialty retailer earned $139.20 million during the quarter, compared to analyst estimates of $125.20 million. Medifast had a net margin of 10.95% and a return on equity of 43.45%. Medifast's quarterly revenue was up 80.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.55 EPS. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Medifast.

Medifast updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.45-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.47. The company issued revenue guidance of $492.5-497.5 million, compared to the consensus revenue estimate of $470.31 million.Medifast also updated its FY 2018 guidance to $4.45-4.50 EPS.

2 brokerages have issued 1-year price targets for Medifast's shares. Their forecasts range from $249.00 to $249.00. On average, they anticipate Medifast's stock price to reach $249.00 in the next year. This suggests a possible upside of 57.3% from the stock's current price. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Headlines about MED stock have been trending somewhat negative on Friday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medifast earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave media stories about the specialty retailer a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.

Some companies that are related to Medifast include MCCORMICK & CO /SH (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Medifast's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.16%), Renaissance Technologies LLC (8.01%), Dimensional Fund Advisors LP (5.73%), Acadian Asset Management LLC (3.57%), Bank of New York Mellon Corp (1.60%) and MERIAN GLOBAL INVESTORS UK Ltd (1.21%). Company insiders that own Medifast stock include Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Man Group plc, TIAA CREF Investment Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, O Shaughnessy Asset Management LLC and Seizert Capital Partners LLC. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Constance J Hallquist, Glenn W Welling and Michael C Macdonald. View Insider Buying and Selling for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, Robeco Institutional Asset Management B.V., Robeco Institutional Asset Management B.V., SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Chartwell Investment Partners LLC and Bank of New York Mellon Corp. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Glenn W Welling, Michael A Hoer and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $158.25.

Medifast has a market capitalization of $1.94 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

The official website for Medifast is http://www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]